ONCY
Oncolytics Biotech Inc
0.6745$
+1.7%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 96.9% | 98.3% | 97.8% | 98.2% | 97.2% | 96.3% | 98.2% | 97.9% | 95.6% | 98.3% | 93.5% | 90.3% | |
| 82.3% | 87.7% | 81.5% | 65.2% | 92.2% | 72.0% | 90.9% | 89.9% | 31.2% | 89.9% | 79.0% | 68.6% | |
| 94.1% | 95.2% | 95.7% | 65.2% | 92.2% | 72.0% | 90.9% | 89.9% | 86.1% | 89.9% | 79.0% | 68.6% | |
| 1.1% | 1.2% | 0.4% | 26.5% | 0.3% | 10.5% | 0.3% | 1.9% | 1.4% | 0.0% | 0.3% | 7.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 2.6% | 0.6% | 2.2% | 1.8% | 2.8% | 3.7% | 1.8% | 2.1% | 1.7% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 19.6% | 9.9% | 27.6% | 54.4% | 58.3% | 100.5% | 27.9% | 21.3% | 29.0% | 29.0% | 70.4% | 150.1% | |
| 19.6% | 9.9% | 27.6% | 28.8% | 18.9% | 65.5% | 7.9% | 5.9% | 10.6% | 10.9% | 33.1% | 80.5% | |
| 0.0% | 0.0% | 0.0% | 8.5% | 0.0% | 1.7% | 0.7% | 0.6% | 0.6% | 0.3% | 1.4% | 2.5% | |
| 19.6% | 9.9% | 27.6% | 20.3% | 12.3% | 0.0% | 5.3% | 1.3% | 6.0% | 2.8% | 5.4% | 46.2% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 80.4% | 90.1% | 72.4% | 45.6% | 41.7% | -0.5% | 72.1% | 78.7% | 71.0% | 71.0% | 29.6% | -50.1% | |
| -1,453.9% | -962.9% | -1,889.3% | -1,622.3% | -2,095.4% | -1,753.0% | -1,068.9% | -857.5% | -1,120.3% | -1,148.9% | -2,366.4% | -5,664.7% | |
| 53.8% | 43.3% | 85.5% | 76.8% | 107.7% | 112.6% | 117.4% | 116.6% | 155.4% | 174.2% | 378.9% | 921.4% |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.